EWTX - Quick Take - Positive CIRRUS Part D data and favorable AF rates support the EDG-7500 story

Research evidence excerpt

EWTX - Quick Take - Positive CIRRUS Part D data and favorable AF rates support the EDG-7500 story

Truist Securities

Equity Research Report June 16, 2026

HEALTHCARE: Biotech Edgewise Therapeutics, Inc. (EWTX)

EWTX - Quick Take - Positive CIRRUS Part D data and favorable Srikripa Devarakonda, Ph.D.

212-303-4173 AF rates support the EDG-7500 story

Srikripa.Devarakonda@truist.com

Alexander Xenakis BOTTOM LINE: Today's data release of positive Ph2 data showed EDG-7500 is

212-590-0954 efficacious and well-tolerated in both oHCM and nHCM patients & we continue to view

Alexander.Xenakis@truist.com this drug as differentiated on LVEF profile. The stock is down pre-market today despite

data that we believe indicate an active drug with a differentiated safety profile that could

Anna Li make it best-in-class. We believe investors may be concerned about enrollment timelines,

212-326-6090 and the potential necessity for Edgewise to run a head-to-head trial with approved CMIs,

Anna.Li@truist.com and the wait for the phase 3 data that will be several years out.

We think the Part D (12-week) data support substantial efficacy with safety that support

the potential for a REMS-free alternative to existing CMIs. The Ph2 Part D data showed

Current Price (Jun. 15, $35.21 no meaningful changes in LVEF including LVEF < 50% and there were 2 (3.8%) cases of

2026) new onset atrial fibrillation events that were both deemed unrelated to study drug by the

Stock Rating BUY investigator.

Unchanged In oHCM patients, EDG-7500 resulted in significant improvements in LVOT-G with 90%

Price Target $52.00 of patients demonstrating improvement in hemodynamic measures and mean 24-point increase in KCCQ. 74% of patients also achieved favorable impact to NT-proBNP levels